This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Potential Marker of Recurrent Melanoma

Jan H. Wong, MD; Shi-Hong Xu; Rishab K. Gupta, PhD; Donald L. Morton, MD

Arch Surg. 1990;125(2):187-191.

Abstract
• To determine the potential utility of antigen-specific immune complex analysis, we developed a competitive enzyme-linked immunosorbent assay utilizing polyclonal human antibody to detect tumor-associated antigen-specific immune complexes. Sera from 10 normal volunteers and 19 patients with recurrent melanoma were studied. Patients with recurrent melanoma had a mean ± SD percent inhibition of 27.6% ± 29.8% in contrast to normal individuals with a mean value of 8.4% ± 17.8%. A monoclonal antibody (MAb JSI) was developed following immunization with a partially purified antigen. Utilizing MAb JSI, we developed a "sandwich" enzyme-linked immunosorbent assay and studied sera from 45 normal volunteers and 44 patients with cancer with recurrent melanoma. Results were expressed as a percent maximum binding of a positive control. The mean ± SD percent maximum binding for normal subjects was 4.9% ± 7.7% in contrast to sera from patients with melanoma who had a mean of 38.3% ±33.3%. Serial analysis of four patients with melanoma with tumor-associated antigen-specific immune complexes demonstrated the presence of tumor-associated antigen-specific immune complexes up to 12 years prior to clinical recurrence.

(Arch Surg. 1990;125:187-191)

Author Affiliations
From the Division of Surgical Oncology, John Wayne Cancer Clinic, Armand Hammer Laboratories, Jonsson Comprehensive Cancer Center, UCLA School of Medicine (Drs Wong, Gupta, and Morton, and Ms Xu); and the Surgical Service, Section of Surgical Oncology, Sepulveda (Calif) Veterans Administration Medical Center (Dr Wong). Dr Wong is a recipient of the Career Development Award from the American Cancer Society.

Footnotes
Accepted for publication November 4, 1989.

Read before the 42nd Annual Meeting of the Society of Surgical Oncology, San Francisco, Calif, May 23, 1989.

Reprint requests to Factor Bldg, Ninth Floor, UCLA School of Medicine, Los Angeles, CA 90024 (Dr Wong).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy
Chung et al.
JCO 2003;21:313-319.
ABSTRACT | FULL TEXT  

Prospective Evaluation of the Use of Antigen-Specific Immune Complexes in Predicting the Development of Recurrent Melanoma
Wong et al.
Arch Surg 1991;126:1450-1454.
ABSTRACT